MK-4830
Biological
Merck Sharp & Dohme Corporation
Total Payments
$4.5M
Transactions
586
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $2.8M | 463 | 0 |
| 2019 | $1.5M | 93 | 1 |
| 2018 | $196,775 | 30 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.5M | 585 | 100.0% |
| Food and Beverage | $95.00 | 1 | 0.0% |
Payments by Type
Research
$4.5M
585 transactions
General
$95.00
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1, Open-label, Multi-Arm, Multi-Site Study of MK-4830 anti-ILT4 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors | Merck Sharp & Dohme Corporation | $4.4M | 0 |
| A Phase 1, Open-label, Multi-Arm, Multi-Site Study of MK-4830 (anti-ILT4) as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors | Merck Sharp & Dohme Corporation | $75,815 | 0 |
Top Doctors Receiving Payments for MK-4830
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Antonio, TX | $4.5M | 585 |
| , MD PHD | Internal Medicine | Detroit, MI | $95.00 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $4.5M
- Total Doctors 1
- Transactions 586
About MK-4830
MK-4830 is a biological associated with $4.5M in payments to 1 healthcare providers, recorded across 586 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2018 to 2020. In 2020, $2.8M was paid across 463 transactions to 0 doctors.
The most common payment nature for MK-4830 is "Unspecified" ($4.5M, 100.0% of total).
MK-4830 is associated with 2 research studies, including "A Phase 1, Open-label, Multi-Arm, Multi-Site Study of MK-4830 anti-ILT4 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors" ($4.4M).